[
  {
    "title": "百济神州(688235.SH)：百泽安用于治疗一线不可切除或转移性肝细胞癌新适应症上市许可申请获得受理",
    "href": "http://stock.jrj.com.cn/2022/12/30221837251345.shtml",
    "datetime": "2022-12-30 22:18:04",
    "code": "688235"
  },
  {
    "title": "“金智奖”2022金融界上市公司价值评选结果揭晓 百济神州等10家公司荣获中国医药生物产业赛道优胜奖",
    "href": "http://stock.jrj.com.cn/2022/12/30161137249738.shtml",
    "datetime": "2022-12-30 16:11:19",
    "code": "688235"
  },
  {
    "title": "百济神州AH齐涨 摩通看好百悦泽长期销售预期",
    "href": "http://stock.jrj.com.cn/2022/12/21102637227614.shtml",
    "datetime": "2022-12-21 10:26:49",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：将在2022ASH年会上展示ALPINE试验终期分析结果最新突破摘要",
    "href": "http://stock.jrj.com.cn/2022/11/23080737159458.shtml",
    "datetime": "2022-11-23 08:07:22",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：欧盟委员会批准百悦泽用于治疗慢性淋巴细胞白血病成人患者",
    "href": "http://stock.jrj.com.cn/2022/11/17201437147919.shtml",
    "datetime": "2022-11-17 20:14:29",
    "code": "688235"
  },
  {
    "title": "晚间公告全知道：百济神州前三季度净亏百亿！八连板天鹅股份提示风险 公司基本面未发生重大变化",
    "href": "http://stock.jrj.com.cn/2022/11/09212337125523.shtml",
    "datetime": "2022-11-09 21:23:35",
    "code": "688235"
  },
  {
    "title": "百济神州2022第三季度保持强劲增长，产品全球收入近24亿元",
    "href": "http://stock.jrj.com.cn/2022/11/09210237125498.shtml",
    "datetime": "2022-11-09 21:02:21",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)第三季度产品收入为23.93亿元、同比上升92.2%",
    "href": "http://stock.jrj.com.cn/2022/11/09203037125403.shtml",
    "datetime": "2022-11-09 20:30:25",
    "code": "688235"
  },
  {
    "title": "百济神州：前三季度净亏损104.34亿元",
    "href": "http://stock.jrj.com.cn/2022/11/09202837125376.shtml",
    "datetime": "2022-11-09 20:28:00",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：欧盟委员会批准百悦泽(泽布替尼胶囊)用于治疗边缘区淋巴瘤成人患者",
    "href": "http://stock.jrj.com.cn/2022/11/02191237107582.shtml",
    "datetime": "2022-11-02 19:12:48",
    "code": "688235"
  },
  {
    "title": "百济神州：欧盟委员会批准百悦泽用于治疗边缘区淋巴瘤成人患者",
    "href": "http://stock.jrj.com.cn/2022/11/02191137107545.shtml",
    "datetime": "2022-11-02 19:11:01",
    "code": "688235"
  },
  {
    "title": "百济神州：百悦泽获欧洲药品管理局人用药品委员会积极意见",
    "href": "http://stock.jrj.com.cn/2022/10/14184237056924.shtml",
    "datetime": "2022-10-14 18:42:36",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：百悦泽(泽布替尼胶囊)获欧洲药品管理局人用药品委员会积极意见",
    "href": "http://stock.jrj.com.cn/2022/10/14183437056918.shtml",
    "datetime": "2022-10-14 18:34:29",
    "code": "688235"
  },
  {
    "title": "百济神州：百悦泽获无进展生存期的优效性结果",
    "href": "http://stock.jrj.com.cn/2022/10/14114037055282.shtml",
    "datetime": "2022-10-14 11:40:37",
    "code": "688235"
  },
  {
    "title": "百济神州(6160.HK)连续第二日上涨 机构称临床优效数据夯实泽布替尼国际化销售放量基石",
    "href": "http://stock.jrj.com.cn/2022/10/14092737054749.shtml",
    "datetime": "2022-10-14 09:27:55",
    "code": "688235"
  },
  {
    "title": "百济神州泽布替尼全球3期头对头研究达到PFS优效性，再证同类最优潜力",
    "href": "http://stock.jrj.com.cn/2022/10/13121837052363.shtml",
    "datetime": "2022-10-13 12:18:19",
    "code": "688235"
  },
  {
    "title": "港股开盘：恒生指数微跌0.38点，百济神州涨近15%",
    "href": "http://stock.jrj.com.cn/2022/10/13092537051827.shtml",
    "datetime": "2022-10-13 09:25:25",
    "code": "688235"
  },
  {
    "title": "艾德生物(300685.SZ)与百济神州达成靶向药物临床研究合作",
    "href": "http://stock.jrj.com.cn/2022/10/11165537047327.shtml",
    "datetime": "2022-10-11 16:55:44",
    "code": "688235"
  },
  {
    "title": "百济神州：百悦泽被推荐用于治疗WM",
    "href": "http://stock.jrj.com.cn/2022/09/20145237007858.shtml",
    "datetime": "2022-09-20 14:52:12",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)：百悦泽获欧洲药品管理局人用药品委员会积极意见，支持其用于治疗边缘区淋巴瘤成人患者",
    "href": "http://stock.jrj.com.cn/2022/09/19200637005962.shtml",
    "datetime": "2022-09-19 20:06:06",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：百悦泽获欧洲药品管理局人用药品委员会积极意见",
    "href": "http://stock.jrj.com.cn/2022/09/19193537005857.shtml",
    "datetime": "2022-09-19 19:35:18",
    "code": "688235"
  },
  {
    "title": "百济神州：百悦泽（泽布替尼胶囊）获欧洲药品管理局人用药品委员会积极意见",
    "href": "http://stock.jrj.com.cn/2022/09/19191737005772.shtml",
    "datetime": "2022-09-19 19:17:36",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)根据购股权计划发行85.58万股",
    "href": "http://stock.jrj.com.cn/2022/09/13074636989904.shtml",
    "datetime": "2022-09-13 07:46:46",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：在2022年欧洲肿瘤内科学会上展示百泽安最新临床数据",
    "href": "http://stock.jrj.com.cn/2022/09/12163736989345.shtml",
    "datetime": "2022-09-12 16:37:40",
    "code": "688235"
  },
  {
    "title": "百济神州（688235.SH/6160.HK/BGNE.US）：全球创新领航，产品收入强劲增长132.2%",
    "href": "http://stock.jrj.com.cn/2022/09/01114036962249.shtml",
    "datetime": "2022-09-01 11:40:14",
    "code": "688235"
  },
  {
    "title": "亏损同比扩大167%！百济神州2022年上半年净亏损66.64亿元",
    "href": "http://stock.jrj.com.cn/2022/08/31092536956349.shtml",
    "datetime": "2022-08-31 09:25:51",
    "code": "688235"
  },
  {
    "title": "百济神州半年报：商业化业绩显著增长 未来多项里程碑备受期待",
    "href": "http://stock.jrj.com.cn/2022/08/31074336955889.shtml",
    "datetime": "2022-08-31 07:43:57",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行17.55万股",
    "href": "http://stock.jrj.com.cn/2022/08/31071636955760.shtml",
    "datetime": "2022-08-31 07:16:02",
    "code": "688235"
  },
  {
    "title": "百济神州A股2022半年报：产品收入同比增长翻倍，重视商业化、研发双提升",
    "href": "http://stock.jrj.com.cn/2022/08/30210136954621.shtml",
    "datetime": "2022-08-30 21:01:37",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：百泽安(替雷利珠单抗注射液)新适应症上市许可申请获受理",
    "href": "http://stock.jrj.com.cn/2022/08/23191836927433.shtml",
    "datetime": "2022-08-23 19:18:28",
    "code": "688235"
  },
  {
    "title": "百济神州：百泽安（替雷利珠单抗注射液）新适应症上市许可申请获得受理",
    "href": "http://stock.jrj.com.cn/2022/08/23191536927419.shtml",
    "datetime": "2022-08-23 19:15:32",
    "code": "688235"
  },
  {
    "title": "上半年亏损扩大至66.64亿元，百济神州到底“玩哪般”？",
    "href": "http://stock.jrj.com.cn/2022/08/11090236889420.shtml",
    "datetime": "2022-08-11 09:02:46",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：百泽安全球3期临床试验RATIONALE 301研究达到主要终点",
    "href": "http://stock.jrj.com.cn/2022/08/09181936883659.shtml",
    "datetime": "2022-08-09 18:19:22",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)授出可认购1.45万股美国存托股份的购股权",
    "href": "http://stock.jrj.com.cn/2022/08/09174836883473.shtml",
    "datetime": "2022-08-09 17:48:47",
    "code": "688235"
  },
  {
    "title": "半导体继续火爆，多只芯片股涨停！医药股大反弹，百济神州涨超11%！赚钱效应回归，5只新股首日齐齐大涨",
    "href": "http://stock.jrj.com.cn/2022/08/05122036873224.shtml",
    "datetime": "2022-08-05 12:20:25",
    "code": "688235"
  },
  {
    "title": "百济神州2022年半年度营收42亿元，同比下降14%",
    "href": "http://stock.jrj.com.cn/2022/08/05102436872897.shtml",
    "datetime": "2022-08-05 10:24:59",
    "code": "688235"
  },
  {
    "title": "百济神州2022年上半年业绩亮眼，产品收入5.661亿美元，同比增长131.3%",
    "href": "http://stock.jrj.com.cn/2022/08/04194136871322.shtml",
    "datetime": "2022-08-04 19:41:07",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)半年度产品收入36.76亿元、同比上升132.2%",
    "href": "http://stock.jrj.com.cn/2022/08/04192136871225.shtml",
    "datetime": "2022-08-04 19:21:46",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)：刘洋接替李振兴担任持续督导保荐代表人",
    "href": "http://stock.jrj.com.cn/2022/07/25174436840546.shtml",
    "datetime": "2022-07-25 17:44:24",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)拟8月4日举行审计委员会会议审批中期业绩",
    "href": "http://stock.jrj.com.cn/2022/07/21061536830274.shtml",
    "datetime": "2022-07-21 06:15:53",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行1.3万股",
    "href": "http://stock.jrj.com.cn/2022/07/18074936819628.shtml",
    "datetime": "2022-07-18 07:49:47",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)更新百泽安治疗二线食管鳞状细胞癌在美新药上市许可申请(BLA)审评状态",
    "href": "http://stock.jrj.com.cn/2022/07/14181236812146.shtml",
    "datetime": "2022-07-14 18:12:48",
    "code": "688235"
  },
  {
    "title": "百济神州：与深信生物达成全球战略合作",
    "href": "http://stock.jrj.com.cn/2022/07/06205436788460.shtml",
    "datetime": "2022-07-06 20:54:55",
    "code": "688235"
  },
  {
    "title": "百济神州(6160.HK)高开近12% 隔夜美股收涨超16%",
    "href": "http://stock.jrj.com.cn/2022/07/06092636785937.shtml",
    "datetime": "2022-07-06 09:26:45",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行26.43万股",
    "href": "http://stock.jrj.com.cn/2022/07/04083036778552.shtml",
    "datetime": "2022-07-04 08:30:19",
    "code": "688235"
  },
  {
    "title": "百济神州在2022年欧洲肿瘤内科学会世界胃肠癌大会上展示百泽安最新数据",
    "href": "http://stock.jrj.com.cn/2022/07/01112036774477.shtml",
    "datetime": "2022-07-01 11:20:00",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)在2022年欧洲肿瘤内科学会世界胃肠癌大会上展示百泽安(替雷利珠单抗注射液)最新数据",
    "href": "http://stock.jrj.com.cn/2022/06/30162236771623.shtml",
    "datetime": "2022-06-30 16:22:05",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行7.75万股",
    "href": "http://stock.jrj.com.cn/2022/06/30070936769935.shtml",
    "datetime": "2022-06-30 07:09:26",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行14.37万股",
    "href": "http://stock.jrj.com.cn/2022/06/29061336766346.shtml",
    "datetime": "2022-06-29 06:13:21",
    "code": "688235"
  },
  {
    "title": "百济神州授出85.8万股美国存托股份的购股权",
    "href": "http://stock.jrj.com.cn/2022/06/27091636759884.shtml",
    "datetime": "2022-06-27 09:16:50",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行60.26万股",
    "href": "http://stock.jrj.com.cn/2022/06/27074036759693.shtml",
    "datetime": "2022-06-27 07:40:09",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)授出可认购85.8万股美国存托股份的购股权",
    "href": "http://stock.jrj.com.cn/2022/06/27073836759663.shtml",
    "datetime": "2022-06-27 07:38:02",
    "code": "688235"
  },
  {
    "title": "百济神州：陈永正辞任公司独立非执行董事职务及董事会专门委员会相应职务",
    "href": "http://stock.jrj.com.cn/2022/06/23101336752268.shtml",
    "datetime": "2022-06-23 10:13:59",
    "code": "688235"
  },
  {
    "title": "百济神州：百泽安新适应症上市许可申请获得药监局受理",
    "href": "http://stock.jrj.com.cn/2022/06/22103136748808.shtml",
    "datetime": "2022-06-22 10:31:30",
    "code": "688235"
  },
  {
    "title": "港股异动 | 百济神州涨7% 百泽安新适应症上市许可申请获得受理",
    "href": "http://stock.jrj.com.cn/2022/06/22094536748593.shtml",
    "datetime": "2022-06-22 09:45:02",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：百泽安新适应症上市许可申请获得受理",
    "href": "http://stock.jrj.com.cn/2022/06/21190736747268.shtml",
    "datetime": "2022-06-21 19:07:30",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行222.7万股",
    "href": "http://stock.jrj.com.cn/2022/06/20074836741118.shtml",
    "datetime": "2022-06-20 07:48:56",
    "code": "688235"
  },
  {
    "title": "百济神州（688235）：于电话会议举行投资者关系活动",
    "href": "http://stock.jrj.com.cn/2022/06/17092136736784.shtml",
    "datetime": "2022-06-17 09:21:17",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行188.5万股",
    "href": "http://stock.jrj.com.cn/2022/06/17064336736450.shtml",
    "datetime": "2022-06-17 06:43:08",
    "code": "688235"
  },
  {
    "title": "百济神州：BTK抑制剂百悦泽已在全球50个市场获批",
    "href": "http://stock.jrj.com.cn/2022/06/14151036727509.shtml",
    "datetime": "2022-06-14 15:10:35",
    "code": "688235"
  },
  {
    "title": "百济神州：药监局批准百泽安用于治疗复发或转移性鼻咽癌",
    "href": "http://stock.jrj.com.cn/2022/06/13104936723277.shtml",
    "datetime": "2022-06-13 10:49:50",
    "code": "688235"
  },
  {
    "title": "百济神州：国家药监局批准百泽安用于治疗复发或转移性鼻咽癌",
    "href": "http://stock.jrj.com.cn/2022/06/10210036720652.shtml",
    "datetime": "2022-06-10 21:00:13",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)在2022年欧洲血液学协会年会上公布血液学产品组合研究数据",
    "href": "http://stock.jrj.com.cn/2022/06/10194136720403.shtml",
    "datetime": "2022-06-10 19:41:52",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：百泽安用于治疗复发或转移性鼻咽癌患者的一线治疗获批",
    "href": "http://stock.jrj.com.cn/2022/06/10193436720299.shtml",
    "datetime": "2022-06-10 19:34:50",
    "code": "688235"
  },
  {
    "title": "百济神州(688235)首次公开发行网下配售限售股于2022年6月15日上市流通",
    "href": "http://stock.jrj.com.cn/2022/06/08091336711218.shtml",
    "datetime": "2022-06-08 09:13:18",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行142.5万股",
    "href": "http://stock.jrj.com.cn/2022/06/06075736704140.shtml",
    "datetime": "2022-06-06 07:57:31",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行20.62万股",
    "href": "http://stock.jrj.com.cn/2022/06/01061836695146.shtml",
    "datetime": "2022-06-01 06:18:24",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)根据受限制股份单位获归属发行25.16万股",
    "href": "http://stock.jrj.com.cn/2022/05/30075836687927.shtml",
    "datetime": "2022-05-30 07:58:11",
    "code": "688235"
  },
  {
    "title": "百济神州：在2022年美国临床肿瘤学会(ASCO)年会展示最新临床数据",
    "href": "http://stock.jrj.com.cn/2022/05/27102836683681.shtml",
    "datetime": "2022-05-27 10:28:41",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)将在ASCO年会上展示实体瘤和血液肿瘤药物组合中的8项研究数据报告",
    "href": "http://stock.jrj.com.cn/2022/05/27081636683226.shtml",
    "datetime": "2022-05-27 08:16:46",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)将在ASCO年会上展示丰富且成熟的肿瘤学药物组合临床数据",
    "href": "http://stock.jrj.com.cn/2022/05/27072236683095.shtml",
    "datetime": "2022-05-27 07:22:01",
    "code": "688235"
  },
  {
    "title": "富时罗素最新发布！近800亿锂电巨头被剔除，什么情况？",
    "href": "http://stock.jrj.com.cn/2022/05/21134236667889.shtml",
    "datetime": "2022-05-21 13:42:25",
    "code": "688235"
  },
  {
    "title": "【互动】百济神州：公司通过多种货币产生开支、获得收入 会择机采取多种措施防范汇率波动风险",
    "href": "http://stock.jrj.com.cn/2022/05/18145436658462.shtml",
    "datetime": "2022-05-18 14:54:03",
    "code": "688235"
  },
  {
    "title": "百济神州（688235.SH/6160.HK/BGNE.US）：入选MSCI中国A股在岸指数成分股，全球化增长加速",
    "href": "http://stock.jrj.com.cn/2022/05/16091336649880.shtml",
    "datetime": "2022-05-16 09:13:35",
    "code": "688235"
  },
  {
    "title": "止盈转亏 百济神州2022年一季度净亏损28.66亿元",
    "href": "http://stock.jrj.com.cn/2022/05/14101836648644.shtml",
    "datetime": "2022-05-14 10:18:54",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)授出购股权",
    "href": "http://stock.jrj.com.cn/2022/05/11063436628919.shtml",
    "datetime": "2022-05-11 06:34:10",
    "code": "688235"
  },
  {
    "title": "合作收入同比下降逾九成，百济神州2022年首季归母净亏损28.66亿元",
    "href": "http://stock.jrj.com.cn/2022/05/06103236577385.shtml",
    "datetime": "2022-05-06 10:32:05",
    "code": "688235"
  },
  {
    "title": "百济神州：一季度净亏损28.66亿元",
    "href": "http://stock.jrj.com.cn/2022/05/05192836571320.shtml",
    "datetime": "2022-05-05 19:28:14",
    "code": "688235"
  },
  {
    "title": "2021年六成医药股营收净利双增，百济神州成“亏损王”",
    "href": "http://stock.jrj.com.cn/2022/05/05121936567787.shtml",
    "datetime": "2022-05-05 12:19:35",
    "code": "688235"
  },
  {
    "title": "百济神州2021年亏损97.48亿同比亏损减少 总裁吴晓滨薪酬1057.7万",
    "href": "http://stock.jrj.com.cn/2022/05/04155036556908.shtml",
    "datetime": "2022-05-04 15:50:55",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)根据受限制股份单位获归属发行64.91万股",
    "href": "http://stock.jrj.com.cn/2022/05/03080836540331.shtml",
    "datetime": "2022-05-03 08:08:14",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)2021年年报：营收大幅增长257.94%、研发投入占营收的比例达125.69%",
    "href": "http://stock.jrj.com.cn/2022/04/29145236504064.shtml",
    "datetime": "2022-04-29 14:52:22",
    "code": "688235"
  },
  {
    "title": "百济神州披露2021年年报 实现营收75.89亿元",
    "href": "http://stock.jrj.com.cn/2022/04/29084336500397.shtml",
    "datetime": "2022-04-29 08:43:01",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)：预计5月5日发布首财季财务业绩",
    "href": "http://stock.jrj.com.cn/2022/04/21061836415586.shtml",
    "datetime": "2022-04-21 06:18:52",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：将公布百泽安3期临床试验RATIONALE-309的更新数据分析",
    "href": "http://stock.jrj.com.cn/2022/04/19200136401988.shtml",
    "datetime": "2022-04-19 20:01:16",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)：国家药监局批准百泽安用于食管鳞状细胞癌的二线治疗",
    "href": "http://stock.jrj.com.cn/2022/04/19072936392614.shtml",
    "datetime": "2022-04-19 07:29:49",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)：建议授予董事受限制股份单位",
    "href": "http://stock.jrj.com.cn/2022/04/19071836392571.shtml",
    "datetime": "2022-04-19 07:18:01",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：国家药监局批准百泽安用于食管鳞状细胞癌的二线治疗",
    "href": "http://stock.jrj.com.cn/2022/04/15182536346017.shtml",
    "datetime": "2022-04-15 18:25:51",
    "code": "688235"
  },
  {
    "title": "科创板公司年度业绩速览：超9成公司实现盈利 百济神州成“亏损王”",
    "href": "http://stock.jrj.com.cn/kcb/2022/04/11075836299211.shtml",
    "datetime": "2022-04-11 07:58:05",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)根据员工购股权计划发行6266股",
    "href": "http://stock.jrj.com.cn/2022/04/08063436270556.shtml",
    "datetime": "2022-04-08 06:34:36",
    "code": "688235"
  },
  {
    "title": "百济神州：百泽安(替雷利珠单抗注射液)新适应症上市许可申请获得欧洲药品管理局受理",
    "href": "http://stock.jrj.com.cn/2022/04/07113236267277.shtml",
    "datetime": "2022-04-07 11:32:39",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行37.21万股",
    "href": "http://stock.jrj.com.cn/2022/04/01080736244691.shtml",
    "datetime": "2022-04-01 08:07:30",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行16.4万股",
    "href": "http://stock.jrj.com.cn/2022/03/30061436175679.shtml",
    "datetime": "2022-03-30 06:14:04",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：国家药监局批准百泽安用于治疗微卫星高度不稳定型或错配修复基因缺陷型实体瘤患者",
    "href": "http://stock.jrj.com.cn/2022/03/11185934815127.shtml",
    "datetime": "2022-03-11 18:59:31",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)根据购股权计划发行66.09万股",
    "href": "http://stock.jrj.com.cn/2022/03/09063234543222.shtml",
    "datetime": "2022-03-09 06:32:17",
    "code": "688235"
  },
  {
    "title": "股价从顶点跌去三成 中国创新药三地上市公司百济神州2021年预亏97亿元",
    "href": "http://stock.jrj.com.cn/2022/03/01085434503876.shtml",
    "datetime": "2022-03-01 08:54:00",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行23.65万股",
    "href": "http://stock.jrj.com.cn/2022/03/01080334503233.shtml",
    "datetime": "2022-03-01 08:03:22",
    "code": "688235"
  },
  {
    "title": "百济神州业绩快报：2021年净亏损97.48亿元",
    "href": "http://stock.jrj.com.cn/2022/02/25204934468406.shtml",
    "datetime": "2022-02-25 20:49:57",
    "code": "688235"
  },
  {
    "title": "博腾医疗涨超10%，美迪西、百济神州涨超9%，创新药沪深港ETF（517110）涨超3%",
    "href": "http://stock.jrj.com.cn/2022/02/25103834464009.shtml",
    "datetime": "2022-02-25 10:38:09",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：百悦泽(泽布替尼胶囊)新适应症上市许可申请获受理",
    "href": "http://stock.jrj.com.cn/2022/02/22180934435363.shtml",
    "datetime": "2022-02-22 18:09:13",
    "code": "688235"
  },
  {
    "title": "151家医药公司业绩前瞻：16家利润或超10亿，百济神州为“亏损王”",
    "href": "http://stock.jrj.com.cn/2022/02/18080734384313.shtml",
    "datetime": "2022-02-18 08:07:05",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行8606股",
    "href": "http://stock.jrj.com.cn/2022/02/17073534378201.shtml",
    "datetime": "2022-02-17 07:35:58",
    "code": "688235"
  },
  {
    "title": "港股异动 | 百济神州涨5% 2021年四季度继为高瓴第一重仓股",
    "href": "http://stock.jrj.com.cn/2022/02/16095234363537.shtml",
    "datetime": "2022-02-16 09:52:39",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)2月28日举行审计委员会会议审批全年业绩",
    "href": "http://stock.jrj.com.cn/2022/02/15173834354364.shtml",
    "datetime": "2022-02-15 17:38:22",
    "code": "688235"
  },
  {
    "title": "持续亏损、核心技术人员职务调整、股价走低，百济神州还好吗？",
    "href": "http://stock.jrj.com.cn/2022/02/15100934352498.shtml",
    "datetime": "2022-02-15 10:09:00",
    "code": "688235"
  },
  {
    "title": "和誉-B(02256.HK)与百济神州达成合作协定开展ABSK091(AZD4547)与替雷利珠单抗联合用药临床研究",
    "href": "http://stock.jrj.com.cn/2022/02/15063634351670.shtml",
    "datetime": "2022-02-15 06:36:05",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)：Margaret Han Dugan和Alessandro Riva获任命为独立非执董",
    "href": "http://stock.jrj.com.cn/2022/02/04080034285141.shtml",
    "datetime": "2022-02-04 08:00:03",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行35.22万股",
    "href": "http://stock.jrj.com.cn/2022/02/04074234285071.shtml",
    "datetime": "2022-02-04 07:42:49",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)授出购股权",
    "href": "http://stock.jrj.com.cn/2022/01/31124234261724.shtml",
    "datetime": "2022-01-31 12:42:13",
    "code": "688235"
  },
  {
    "title": "港股异动 | 百济神州高开5% 百悦泽新适应症上市许可申请获受理并获突破性疗法认定",
    "href": "http://stock.jrj.com.cn/2022/01/31092734261335.shtml",
    "datetime": "2022-01-31 09:27:39",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行12.92万股",
    "href": "http://stock.jrj.com.cn/2022/01/31081034261140.shtml",
    "datetime": "2022-01-31 08:10:51",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：百悦泽(泽布替尼胶囊)新适应症上市许可申请获受理并获突破性治疗品种认定",
    "href": "http://stock.jrj.com.cn/2022/01/28175834243620.shtml",
    "datetime": "2022-01-28 17:58:57",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)获The Capital Group增持141.53万股",
    "href": "http://stock.jrj.com.cn/2022/01/25073534208042.shtml",
    "datetime": "2022-01-25 07:35:20",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：百悦泽用于治疗华氏巨球蛋白血症成人患者的新适应症上市申请获得受理",
    "href": "http://stock.jrj.com.cn/2022/01/20175034179171.shtml",
    "datetime": "2022-01-20 17:50:36",
    "code": "688235"
  },
  {
    "title": "投资者建议百济神州成立炼丹部门早日完成神丹炼制 公司回应：目前没有中药在研项目",
    "href": "http://stock.jrj.com.cn/2022/01/12151134149792.shtml",
    "datetime": "2022-01-12 15:11:49",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：百泽安用于局部晚期或转移性非小细胞肺癌患者的二线或三线治疗获批",
    "href": "http://stock.jrj.com.cn/2022/01/06162034129711.shtml",
    "datetime": "2022-01-06 16:20:58",
    "code": "688235"
  },
  {
    "title": "百济神州跌4.06%创新低 募资222亿5券商赚4.7亿",
    "href": "http://stock.jrj.com.cn/2022/01/05170934123796.shtml",
    "datetime": "2022-01-05 17:09:00",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行39.23万股",
    "href": "http://stock.jrj.com.cn/2022/01/03075434103401.shtml",
    "datetime": "2022-01-03 07:54:49",
    "code": "688235"
  },
  {
    "title": "百奥泰(688177.SH)：收到由百济神州支付的3000万美元里程碑付款",
    "href": "http://stock.jrj.com.cn/2021/12/30204934088298.shtml",
    "datetime": "2021-12-30 20:49:47",
    "code": "688235"
  },
  {
    "title": "百济神州：上市即破发 生物科技先锋成价值毁灭者？",
    "href": "http://stock.jrj.com.cn/2021/12/27082434068538.shtml",
    "datetime": "2021-12-27 08:24:45",
    "code": "688235"
  },
  {
    "title": "百济神州：超额配售剩余资金4.97亿元将纳入证券投资者保护基金",
    "href": "http://stock.jrj.com.cn/2021/12/26161034062008.shtml",
    "datetime": "2021-12-26 16:10:19",
    "code": "688235"
  },
  {
    "title": "葛兰、胡昕炜、蔡嵩松被“套”！百济神州破发超20%",
    "href": "http://stock.jrj.com.cn/ipo/2021/12/25123334060937.shtml",
    "datetime": "2021-12-25 12:33:25",
    "code": "688235"
  },
  {
    "title": "百济神州宣布凯泽百��在中国正式供应",
    "href": "http://stock.jrj.com.cn/2021/12/23144934052509.shtml",
    "datetime": "2021-12-23 14:49:15",
    "code": "688235"
  },
  {
    "title": "十年融资七百亿、“烧钱”搞研发 百济神州到底是不是“虚胖”？",
    "href": "http://stock.jrj.com.cn/2021/12/23083834050704.shtml",
    "datetime": "2021-12-23 08:38:15",
    "code": "688235"
  },
  {
    "title": "百济神州A股上市首日破发跌逾16% 三地IPO募资324亿全年或续亏百亿",
    "href": "http://stock.jrj.com.cn/2021/12/16075534022946.shtml",
    "datetime": "2021-12-16 07:55:35",
    "code": "688235"
  },
  {
    "title": "百济神州上市首日破发收跌16.42%：成交额超50亿元 换手率超34%",
    "href": "http://stock.jrj.com.cn/2021/12/15163134019709.shtml",
    "datetime": "2021-12-15 16:31:58",
    "code": "688235"
  },
  {
    "title": "百济神州A股上市首日开盘破发，五家券商包销“天团”压力山大",
    "href": "http://stock.jrj.com.cn/2021/12/15145134019359.shtml",
    "datetime": "2021-12-15 14:51:36",
    "code": "688235"
  },
  {
    "title": "百济神州上市首日破发 中一签浮亏2万元：超100万股遭弃购",
    "href": "http://stock.jrj.com.cn/2021/12/15113134018864.shtml",
    "datetime": "2021-12-15 11:31:58",
    "code": "688235"
  },
  {
    "title": "股民哭了：中一签亏1.8万！刚刚，2000亿巨头上市暴跌！更有这家地产巨头，股债\"双杀\"",
    "href": "http://stock.jrj.com.cn/2021/12/15112234018850.shtml",
    "datetime": "2021-12-15 11:22:30",
    "code": "688235"
  },
  {
    "title": "“A+H+N”三地上市也拯救不了股价？百济神州股价开盘破发，盘中跌幅一度扩大超15%",
    "href": "http://stock.jrj.com.cn/2021/12/15102234018363.shtml",
    "datetime": "2021-12-15 10:22:02",
    "code": "688235"
  },
  {
    "title": "上市首日跌近20%！百济神州惨遭破发，发行价高、公司至今未盈利，此前遭弃购超100万股",
    "href": "http://stock.jrj.com.cn/2021/12/15093334018052.shtml",
    "datetime": "2021-12-15 09:33:33",
    "code": "688235"
  },
  {
    "title": "开盘：A股三大指数集体低开沪指跌0.18％，科创板新股百济神州破发跌超8%",
    "href": "http://stock.jrj.com.cn/2021/12/15092734018014.shtml",
    "datetime": "2021-12-15 09:27:05",
    "code": "688235"
  },
  {
    "title": "首家三地上市企业来了！百济神州将于12月15日在科创板上市",
    "href": "http://stock.jrj.com.cn/2021/12/13195534010049.shtml",
    "datetime": "2021-12-13 19:55:39",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：将于12月15日在科创板上市",
    "href": "http://stock.jrj.com.cn/2021/12/13192634009894.shtml",
    "datetime": "2021-12-13 19:26:28",
    "code": "688235"
  },
  {
    "title": "高瓴等投资机构将迎来“收获季”？百济神州科创板IPO注册生效",
    "href": "http://stock.jrj.com.cn/2021/12/09091933988558.shtml",
    "datetime": "2021-12-09 09:19:35",
    "code": "688235"
  },
  {
    "title": "百济神州科创板上市在即 战略配售者阵容豪华",
    "href": "http://stock.jrj.com.cn/2021/12/08113733984218.shtml",
    "datetime": "2021-12-08 11:37:25",
    "code": "688235"
  },
  {
    "title": "历史罕见！“缴款日”突然暴跌13%，2000亿白马新股遭弃购1.99亿！上市要破发？",
    "href": "http://stock.jrj.com.cn/2021/12/08071933983356.shtml",
    "datetime": "2021-12-08 07:19:00",
    "code": "688235"
  },
  {
    "title": "百济神州披露发行结果：网上投资者弃购近1.99亿元",
    "href": "http://stock.jrj.com.cn/2021/12/07214233981767.shtml",
    "datetime": "2021-12-07 21:42:37",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)披露中签结果：中签号码共8.28万个",
    "href": "http://stock.jrj.com.cn/2021/12/05155133965194.shtml",
    "datetime": "2021-12-05 15:51:17",
    "code": "688235"
  },
  {
    "title": "百济神州：抗癌药多项新增适应症及一款自主研发抗癌新药纳入新版国家医保药品目录",
    "href": "http://stock.jrj.com.cn/2021/12/03123233959513.shtml",
    "datetime": "2021-12-03 12:32:55",
    "code": "688235"
  },
  {
    "title": "百济神州：回拨后网上发行最终中签率为0.035%",
    "href": "http://stock.jrj.com.cn/2021/12/02194633956549.shtml",
    "datetime": "2021-12-02 19:46:41",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：回拨后网上发行最终中签率为0.03515023%",
    "href": "http://stock.jrj.com.cn/2021/12/02190533956446.shtml",
    "datetime": "2021-12-02 19:05:47",
    "code": "688235"
  },
  {
    "title": "百济神州（688235.SH）科创板今日申购，千亿重磅药企来袭",
    "href": "http://stock.jrj.com.cn/2021/12/02100333954187.shtml",
    "datetime": "2021-12-02 10:03:39",
    "code": "688235"
  },
  {
    "title": "即将“三地上市”、高瓴陪跑七年，百济神州凭借什么？",
    "href": "http://stock.jrj.com.cn/2021/12/01140733949368.shtml",
    "datetime": "2021-12-01 14:07:14",
    "code": "688235"
  },
  {
    "title": "百济神州(688235.SH)：IPO定价为192.60元/股 12月2日开启申购",
    "href": "http://stock.jrj.com.cn/2021/11/30191733945408.shtml",
    "datetime": "2021-11-30 19:17:27",
    "code": "688235"
  },
  {
    "title": "百济神州(06160.HK)因受限制股份单位获归属发行22.854万股",
    "href": "http://stock.jrj.com.cn/2021/11/30081733941920.shtml",
    "datetime": "2021-11-30 08:17:44",
    "code": "688235"
  },
  {
    "title": "A股医药板块迎新龙头：高瓴第一重仓百济神州将上科创板",
    "href": "http://stock.jrj.com.cn/2021/11/18143333872169.shtml",
    "datetime": "2021-11-18 14:33:55",
    "code": "688235"
  },
  {
    "title": "即将开启“美股+H股+A股”！百济神州科创板IPO获证监会通过",
    "href": "http://stock.jrj.com.cn/2021/11/17160733866375.shtml",
    "datetime": "2021-11-17 16:07:20",
    "code": "688235"
  },
  {
    "title": "A股头条：海外最大中国股票基金9月加仓A股；证监会同意百济神州等3家公司科创板IPO注册",
    "href": "http://stock.jrj.com.cn/2021/11/17062833863147.shtml",
    "datetime": "2021-11-17 06:28:25",
    "code": "688235"
  },
  {
    "title": "证监会同意百济神州等三家企业科创板IPO注册",
    "href": "http://stock.jrj.com.cn/2021/11/16191633861501.shtml",
    "datetime": "2021-11-16 19:16:01",
    "code": "688235"
  },
  {
    "title": "百济神州前三财季净亏损8.28亿美元，同比收窄26.37%",
    "href": "http://stock.jrj.com.cn/2021/11/08113733822560.shtml",
    "datetime": "2021-11-08 11:37:22",
    "code": "688235"
  },
  {
    "title": "百济神州宣布泽布替尼在澳洲获批治疗套细胞淋巴瘤成人患者",
    "href": "http://stock.jrj.com.cn/2021/10/11111933671944.shtml",
    "datetime": "2021-10-11 11:19:02",
    "code": "688235"
  },
  {
    "title": "百济神州股价创历史新高，总市值接近3300亿港元",
    "href": "http://stock.jrj.com.cn/2021/09/17132433450619.shtml",
    "datetime": "2021-09-17 13:24:26",
    "code": "688235"
  },
  {
    "title": "百济神州直线拉升，恒生医疗ETF（513060）涨2.28%",
    "href": "http://stock.jrj.com.cn/2021/09/17104233449855.shtml",
    "datetime": "2021-09-17 10:42:58",
    "code": "688235"
  },
  {
    "title": "百济神州（6160.HK）涨超5%，恒生医疗ETF（513060）冲高回落",
    "href": "http://stock.jrj.com.cn/2021/09/02141733373921.shtml",
    "datetime": "2021-09-02 14:17:46",
    "code": "688235"
  },
  {
    "title": "百济神州未雨绸缪拓展三个维度 1600多亿市值等待A股考验",
    "href": "http://stock.jrj.com.cn/ipo/2021/08/25084233314245.shtml",
    "datetime": "2021-08-25 08:42:39",
    "code": "688235"
  },
  {
    "title": "泽布替尼又一重磅3期研究取得积极数据，证实在一线慢淋中的治疗地位",
    "href": "http://stock.jrj.com.cn/2021/07/30093433173888.shtml",
    "datetime": "2021-07-30 09:34:35",
    "code": "688235"
  },
  {
    "title": "首家A+H+N三地上市药企要来了？百济神州IPO提交注册“叩响”科创板大门",
    "href": "http://stock.jrj.com.cn/2021/07/29095633168297.shtml",
    "datetime": "2021-07-29 09:56:21",
    "code": "688235"
  },
  {
    "title": "百济神州成功过会 科创板“千亿市值俱乐部”或添新成员",
    "href": "http://stock.jrj.com.cn/2021/06/28183233011180.shtml",
    "datetime": "2021-06-28 18:32:39",
    "code": "688235"
  },
  {
    "title": "资本邦IPO周报：中科英泰撤回申请，百济神州将上会有望成三地上市药企",
    "href": "http://stock.jrj.com.cn/2021/06/27111033002197.shtml",
    "datetime": "2021-06-27 11:10:04",
    "code": "688235"
  },
  {
    "title": "百济神州、中自环保、华强科技6月28日科创板IPO上会",
    "href": "http://stock.jrj.com.cn/2021/06/22095832974697.shtml",
    "datetime": "2021-06-22 09:58:47",
    "code": "688235"
  },
  {
    "title": "华强科技、百济神州、中自环保6月28日科创板首发上会",
    "href": "http://stock.jrj.com.cn/2021/06/21191532970950.shtml",
    "datetime": "2021-06-21 19:15:00",
    "code": "688235"
  },
  {
    "title": "百济神州宣布AdvanTIG-302全球3期临床试验完成首例患者给药",
    "href": "http://stock.jrj.com.cn/2021/06/18104432953137.shtml",
    "datetime": "2021-06-18 10:44:25",
    "code": "688235"
  },
  {
    "title": "利德曼：公司目前不持有百济神州股份也尚未与其建立业务合作",
    "href": "http://stock.jrj.com.cn/2021/06/15162932934852.shtml",
    "datetime": "2021-06-15 16:29:37",
    "code": "688235"
  },
  {
    "title": "微芯生物：百济神州的BTK抑制剂目前还没有获批针对弥漫大B细胞淋巴瘤",
    "href": "http://stock.jrj.com.cn/2021/06/02190732864875.shtml",
    "datetime": "2021-06-02 19:07:05",
    "code": "688235"
  },
  {
    "title": "首个出海本土新药泽布替尼头对头优效性数据亮相！证实疗效与安全性优势",
    "href": "http://stock.jrj.com.cn/2021/06/02105132861896.shtml",
    "datetime": "2021-06-02 10:51:23",
    "code": "688235"
  },
  {
    "title": "自主研发？授权引进？百济神州答科创板二轮问询",
    "href": "http://stock.jrj.com.cn/2021/06/02090732861250.shtml",
    "datetime": "2021-06-02 09:07:33",
    "code": "688235"
  },
  {
    "title": "帕米帕利开发时间早却尚未获批上市原因及合理性？百济神州回复科创板首轮问询",
    "href": "http://stock.jrj.com.cn/2021/05/17135732768871.shtml",
    "datetime": "2021-05-17 13:57:48",
    "code": "688235"
  },
  {
    "title": "PD-1产能是否会过剩？百济神州总裁吴晓滨：相当一段时间内不会",
    "href": "http://stock.jrj.com.cn/2021/04/08193132333615.shtml",
    "datetime": "2021-04-08 19:31:13",
    "code": "688235"
  },
  {
    "title": "百济神州CFO梁恒将交棒于王爱军，后者将于2021年6月30日正式上任",
    "href": "http://stock.jrj.com.cn/2021/03/31131032255166.shtml",
    "datetime": "2021-03-31 13:10:26",
    "code": "688235"
  },
  {
    "title": "“三地上市”再近一步，百济神州科创板IPO获上交所问询",
    "href": "http://stock.jrj.com.cn/2021/03/01094532048219.shtml",
    "datetime": "2021-03-01 09:45:49",
    "code": "688235"
  },
  {
    "title": "日亏千万 百济神州再赴科创板",
    "href": "http://stock.jrj.com.cn/kcb/2021/02/05025831851474.shtml",
    "datetime": "2021-02-05 02:58:00",
    "code": "688235"
  },
  {
    "title": "科创板药企难逃“尚未盈利”掣肘？百济神州拟择第三地上市募资200亿",
    "href": "http://stock.jrj.com.cn/2021/02/03091131841630.shtml",
    "datetime": "2021-02-03 09:11:20",
    "code": "688235"
  },
  {
    "title": "百济神州A股科创板上市获受理，或成为首家A+H+N 3地上市的药企",
    "href": "http://stock.jrj.com.cn/2021/02/01095331827658.shtml",
    "datetime": "2021-02-01 09:53:55",
    "code": "688235"
  },
  {
    "title": "百济神州拟科创板募资200亿元 有望成为国内首家三地上市药企",
    "href": "http://stock.jrj.com.cn/2021/01/29215831811866.shtml",
    "datetime": "2021-01-29 21:58:45",
    "code": "688235"
  },
  {
    "title": "中金公司与高盛高华联席辅导，百济神州欲科创板IPO",
    "href": "http://stock.jrj.com.cn/2021/01/26093031773863.shtml",
    "datetime": "2021-01-26 09:30:27",
    "code": "688235"
  },
  {
    "title": "强强联合，全球品质，国产PD-1单抗“出海”提速",
    "href": "http://stock.jrj.com.cn/2021/01/22093131742785.shtml",
    "datetime": "2021-01-22 09:31:02",
    "code": "688235"
  },
  {
    "title": "百济神州完成科创板上市辅导：或成第一家三地上市的创新药企，高瓴连投8次",
    "href": "http://stock.jrj.com.cn/2021/01/22080431742292.shtml",
    "datetime": "2021-01-22 08:04:05",
    "code": "688235"
  },
  {
    "title": "百济神州子公司与诺华达成抗癌药合作开发协议，涉资超22亿美元",
    "href": "http://stock.jrj.com.cn/2021/01/13135531683469.shtml",
    "datetime": "2021-01-13 13:55:41",
    "code": "688235"
  },
  {
    "title": "诺华获得百济神州PD-1海外市场开发及商业化许可 双方仍可分别探索联合用药可能性",
    "href": "http://stock.jrj.com.cn/2021/01/12191031677844.shtml",
    "datetime": "2021-01-12 19:10:34",
    "code": "688235"
  },
  {
    "title": "全国医保谈判第三日，百济神州、信达生物等PD-1创新药企股价上涨",
    "href": "http://stock.jrj.com.cn/2020/12/16175031503339.shtml",
    "datetime": "2020-12-16 17:50:46",
    "code": "688235"
  },
  {
    "title": "安进血液瘤产品倍利妥国内获批 百济神州负责商业化",
    "href": "http://stock.jrj.com.cn/2020/12/08121731438745.shtml",
    "datetime": "2020-12-08 12:17:43",
    "code": "688235"
  },
  {
    "title": "百济神州上市药品同类销量垫底 冲击科创板能否复制1600亿的估值？",
    "href": "http://stock.jrj.com.cn/2020/12/03112931398564.shtml",
    "datetime": "2020-12-03 11:29:52",
    "code": "688235"
  },
  {
    "title": "百济神州已开始接受中金、高盛高华辅导 或成第一家三地上市的创新药企",
    "href": "http://stock.jrj.com.cn/2020/11/28085131364734.shtml",
    "datetime": "2020-11-28 08:51:05",
    "code": "688235"
  },
  {
    "title": "百济神州要来了 科创板“吸睛”生物医药企业",
    "href": "http://stock.jrj.com.cn/kcb/2020/11/18022131303096.shtml",
    "datetime": "2020-11-18 02:21:43",
    "code": "688235"
  },
  {
    "title": "谋科创板上市 百济神州烧钱何时休",
    "href": "http://stock.jrj.com.cn/kcb/2020/11/17011431295085.shtml",
    "datetime": "2020-11-17 01:14:31",
    "code": "688235"
  },
  {
    "title": "煤老板也想投资生物医药？ 百济神州副总裁汪来：行业已存一定泡沫",
    "href": "http://stock.jrj.com.cn/2020/10/23220131119255.shtml",
    "datetime": "2020-10-23 22:01:14",
    "code": "688235"
  },
  {
    "title": "[中国海诚]公司党委书记、董事长赵国昂一行冒暑赴百济神州项目慰问",
    "href": "http://stock.jrj.com.cn/2020/08/18000030533803.shtml",
    "datetime": "2020-08-18 00:00:00",
    "code": "688235"
  },
  {
    "title": "百济神州Q2产品收入6600万美元创新高 上半年亏损6.99亿美元",
    "href": "http://stock.jrj.com.cn/2020/08/07135830449512.shtml",
    "datetime": "2020-08-07 13:58:29",
    "code": "688235"
  },
  {
    "title": "高瓴资本、安进主动增持 百济神州完成20.8亿美元融资",
    "href": "http://stock.jrj.com.cn/2020/07/15122330248692.shtml",
    "datetime": "2020-07-15 12:23:00",
    "code": "688235"
  },
  {
    "title": "百济神州定增20.8亿美元创纪录 上海莱士上半年业绩预增逾60% | 医资日报",
    "href": "http://stock.jrj.com.cn/2020/07/14190030240564.shtml",
    "datetime": "2020-07-14 19:00:16",
    "code": "688235"
  },
  {
    "title": "百济神州完成20.8亿美元股权融资 高瓴资本、安进参与认购",
    "href": "http://stock.jrj.com.cn/2020/07/14122030237006.shtml",
    "datetime": "2020-07-14 12:20:21",
    "code": "688235"
  },
  {
    "title": "每经数说丨6月上半月新药研发：中国新冠灭活疫苗初步成果良好，百济神州1类新药泽布替尼上市",
    "href": "http://stock.jrj.com.cn/2020/06/23212530001822.shtml",
    "datetime": "2020-06-23 21:25:12",
    "code": "688235"
  },
  {
    "title": "百济神州创新药泽布替尼国内获批上市 将与巨头强生直接竞争",
    "href": "http://stock.jrj.com.cn/2020/06/03172629837047.shtml",
    "datetime": "2020-06-03 17:26:10",
    "code": "688235"
  },
  {
    "title": "[外高桥]百济神州项目开工",
    "href": "http://stock.jrj.com.cn/2020/05/11000031822614.shtml",
    "datetime": "2020-05-11 00:00:00",
    "code": "688235"
  },
  {
    "title": "[外高桥]百济神州项目开工",
    "href": "http://stock.jrj.com.cn/2020/05/08000030324535.shtml",
    "datetime": "2020-05-08 00:00:00",
    "code": "688235"
  },
  {
    "title": "每经数说丨4月上半月新药研发：百济神州PD-1获批第二个适应症，复星医药进口的血小板减少症药物可上市",
    "href": "http://stock.jrj.com.cn/2020/04/21112329337257.shtml",
    "datetime": "2020-04-21 11:23:24",
    "code": "688235"
  },
  {
    "title": "第二批集采落地在即 中选品种之一却生变 涉及多家上市公司",
    "href": "http://stock.jrj.com.cn/2020/03/26172429118986.shtml",
    "datetime": "2020-03-26 17:24:05",
    "code": "688235"
  },
  {
    "title": "代理的一款化疗肿瘤药被暂停进口销售 百济神州：正整改解决",
    "href": "http://stock.jrj.com.cn/2020/03/26142929117913.shtml",
    "datetime": "2020-03-26 14:29:18",
    "code": "688235"
  },
  {
    "title": "百济神州与安进全球肿瘤战略合作及股权投资生效",
    "href": "http://stock.jrj.com.cn/2020/01/03210428626340.shtml",
    "datetime": "2020-01-03 21:04:00",
    "code": "688235"
  },
  {
    "title": "百济神州港股收盘跌6.46% 泽布替尼对比试验数据未达市场预期",
    "href": "http://stock.jrj.com.cn/2019/12/17170828546643.shtml",
    "datetime": "2019-12-17 17:08:28",
    "code": "688235"
  },
  {
    "title": "百济神州吴晓滨：泽布替尼美国商业团队已经建立完毕，患者有望年内用药",
    "href": "http://stock.jrj.com.cn/2019/11/15180728405723.shtml",
    "datetime": "2019-11-15 18:07:45",
    "code": "688235"
  },
  {
    "title": "零突破！百济神州抗癌新药在美获批上市 众多药企抢局BTK抑制剂",
    "href": "http://stock.jrj.com.cn/2019/11/15142128404521.shtml",
    "datetime": "2019-11-15 14:21:13",
    "code": "688235"
  },
  {
    "title": "百济神州抗癌新药在美上市，主攻人类“隐形杀手”",
    "href": "http://stock.jrj.com.cn/2019/11/15113728404070.shtml",
    "datetime": "2019-11-15 11:37:44",
    "code": "688235"
  },
  {
    "title": "百济神州与安进战略合作 后者将27亿美元入股",
    "href": "http://stock.jrj.com.cn/2019/11/01085428336816.shtml",
    "datetime": "2019-11-01 08:54:50",
    "code": "688235"
  },
  {
    "title": "明星股百济神州被做空,6成销售系\"伪造\"两日跌13%,市值蒸发89亿",
    "href": "http://stock.jrj.com.cn/2019/09/06193128102498.shtml",
    "datetime": "2019-09-06 19:31:00",
    "code": "688235"
  },
  {
    "title": "港股股价下跌9% 百济神州回应做空报告：对公司的指控公然造假",
    "href": "http://stock.jrj.com.cn/2019/09/06181228102159.shtml",
    "datetime": "2019-09-06 18:12:35",
    "code": "688235"
  },
  {
    "title": "百济神州中期业绩“回血” 因收回PD-1授权亏损同比收窄",
    "href": "http://stock.jrj.com.cn/2019/08/09154927953954.shtml",
    "datetime": "2019-08-09 15:49:15",
    "code": "688235"
  },
  {
    "title": "百济神州收回旗下PD-1产品授权 新基制药支付1.5亿美元",
    "href": "http://stock.jrj.com.cn/2019/06/18004827716920.shtml",
    "datetime": "2019-06-18 00:48:49",
    "code": "688235"
  },
  {
    "title": "ZW25获FDA快速通道资格 百济神州拥有其亚洲独家开发权",
    "href": "http://stock.jrj.com.cn/2019/05/30205927643221.shtml",
    "datetime": "2019-05-30 20:59:14",
    "code": "688235"
  },
  {
    "title": "明星抗癌药企百济神州的关键年：产品落地竞速 直面“造血”考验",
    "href": "http://stock.jrj.com.cn/2019/05/24190127620119.shtml",
    "datetime": "2019-05-24 19:01:21",
    "code": "688235"
  },
  {
    "title": "百济神州交出港股上市首份成绩单 抗癌药巨子离赚钱有多远？",
    "href": "http://stock.jrj.com.cn/2019/03/05230827122785.shtml",
    "datetime": "2019-03-05 23:08:33",
    "code": "688235"
  },
  {
    "title": "又一款“救命药”有望近期上市 百济神州PD-1新药上市申请获受理",
    "href": "http://stock.jrj.com.cn/2018/09/12110525081032.shtml",
    "datetime": "2018-09-12 11:05:02",
    "code": "688235"
  },
  {
    "title": "百济神州宣布瑞复美在中国获批用于先前未经治疗的多发性骨髓瘤",
    "href": "http://stock.jrj.com.cn/2018/02/28105824166241.shtml",
    "datetime": "2018-02-28 10:58:00",
    "code": "688235"
  }
]